Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
76 of 180 long COVID-associated genes also linked to ME
MRI is particularly valuable in pediatric care due to its non-invasive nature
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The fresh capital will propel Cordance into its first-in-human clinical trial
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Subscribe To Our Newsletter & Stay Updated
